Ultra Drugs Private Limited, a active private limited company, was established on 03 October 2005 in Chandigarh, Chandigarh, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24230CH2005PTC029023. Registered under ROC Roc Chandigarh. it is unlisted. It has an authorized capital of ₹3.50 Cr and a paid-up capital of ₹3.06 Cr.
It upholds a compliant status. Employing 506 professional, Its leadership includes Sandeep Kumar Arora (Director), Minna Jakhar (Director), Sangram Singh (Director). Past directors included Banshidhar Kanhaiyalal, Rajinder Kaur, Malwinderjit Singh Waraich. It holds ₹29.40 Cr open charges and ₹26.77 Cr settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at H.No. 1201 Sector-22 B, Chandigarh, Chandigarh, 160022.
U24230CH2005PTC029023
029023
03 October 2005
₹3.50 Cr
₹3.06 Cr
Roc Chandigarh
Unlisted
Active
Explore comprehensive insights into Ultra Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandeep Kumar Arora | Director | 20 Jan 2019 | Current |
| Minna Jakhar | Director | 14 Jan 2008 | Current |
| Sangram Singh | Director | 30 Jun 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 14 Jan 2008 | Past |
| Pramod Abcsdd | Director | 19 Aug 2014 | Past |
| Pramod Abcsdd | Director | 20 Jan 2019 | Past |
| Pramod Abcsdd | Director | 26 Sep 2018 | Past |
| Pramod Abcsdd | Additional Director | 23 Feb 2008 | Past |
| Pramod Abcsdd | Additional Director | 23 Feb 2008 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Ultra Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.2% increase. The company also saw a substantial fall in profitability, with a 47.18% decrease in profit. The company's net worth moved up by a moderate rise of 7.96%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Ultra Drugs had a promoter holding of 100.00%. The company had 3 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹294,000,000.00
₹267,699,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Jan 2023 | State Bank Of India | ₹18.50 Cr | Open |
| 29 Aug 2021 | Hdfc Bank Limited | ₹1.00 Cr | Open |
| 03 Mar 2021 | Hdfc Bank Limited | ₹1.00 M | Open |
| 28 Dec 2019 | Hdfc Bank Limited | ₹9.50 Cr | Open |
| 28 May 2011 | Director Of Industries Himachal Pradesh | ₹3.00 M | Open |
Explore comprehensive loan charge details -
Ultra Drugs has a workforce of 506 employees as of Sep 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Ultra Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ultra Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Hdfc Bank Limited of Rs. 9.50 Cr registered on 28 Dec 2019 with Charge ID 100320405 was modified on 22 Jul 2025. was documented.
Progress on A charge with State Bank Of India of Rs. 18.50 Cr registered on 24 Jan 2023 with Charge ID 100685124 was modified on 03 May 2025. was documented.
Progress on Ultra Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Ultra Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Chandigarh. was recorded as a recent event.
The activity A charge with State Bank Of India amounted to Rs. 18.50 Cr with Charge ID 100685124 was registered on 24 Jan 2023. was completed.
The activity A charge with Hdfc Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100487596 was registered on 29 Aug 2021. was completed.
The CIN of Ultra Drugs Private Limited is U24230CH2005PTC029023.
Ultra Drugs Private Limited is headquartered at H.No. 1201 Sector-22 B, Chandigarh, Chandigarh, 160022.
Ultra Drugs Private Limited was incorporated on 03 October 2005.
The current directors of Ultra Drugs Private Limited are
The primary industry of Ultra Drugs Private Limited is Manufacturing.
Ultra Drugs Private Limited is unlisted.
The authorized capital of Ultra Drugs Private Limited is ₹3.50 Cr, and the paid-up capital is ₹3.06 Cr.
The compliance status of Ultra Drugs Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX